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Brendon Yew Loong Chua and David C. Jackson*
Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne,
Parkville, VIC, Australia
Immunostimulatory agents provide a new category of anti-microbial agents that activate
the host’s innate immune system allowing control of viral and/or bacterial infections.
The TLR-2 agonist PEG-Pam2Cys has been shown to mediate potent anti-viral activity
against influenza viruses when administered prophylactically (1). Here, we demonstrate
that the treatment of mice with PEG-Pam2Cys does not compromise their ability to
generate adaptive immune responses following subsequent challenge with influenza virus.
The antibody induced in mice pre-treated with Pam2Cys possessed hemagglutination-
inhibiting activities and the CD8+ T-cell responses that were elicited provided protection
against heterologous viral challenge. In the absence of an effective influenza vaccine,
an agent that provides immediate protection against the virus and does not com-
promise the induction of influenza-specific immunity on exposure to infectious virus
provides an opportunity for population immunity to be achieved through natural exposure
to virus.
Keywords: Pam2Cys, toll-like receptor-2, influenza A virus, innate immunity, adaptive immunity
Introduction
Vaccination is currently themost effectivemedical intervention available for prevention of influenza
infection and disease. The efficacy of influenza vaccines is dependent on a match between the viral
strains included in the vaccine and circulating influenza virus strains. Although anti-viral drugs
can diminish symptoms and shorten the duration of illness (2, 3), the suggestion has been made
that in the case of influenza their use can hamper the development of immunological memory (4)
leaving the host susceptible to re-infection when drug treatment ceases. Although anti-influenza
drugs continue to be used effectively in a clinical setting, concerns with anti-viral resistance (5–
7) due to their widespread use have resulted in increased efforts to develop alternative prevention
strategies.
Abbreviations: Ab, antibody; Influenza, influenza A virus; Pam2Cys, S-[2,3-bis(palmitoyloxy)propyl] cysteine; TLR, toll-like
receptor.
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One approach is to harness the rapid anti-microbial responses
of the innate immune system, particularly for pathogens that use
the respiratory portal of entry. Immunostimulatory agents pro-
vide immediate non-specific protection against virulent influenza
challenge (1, 8–10), and in mice, these compounds reduce the
symptoms associated with influenza infection and also the viral
burden reducingmorbidity and promoting survival. Furthermore,
by acting through the innate immune system and not directly
on the pathogen, these immunostimulatory agents are unlikely to
select resistant virus variants.
Many immunostimulatory agents are agonists of toll-like recep-
tors (TLR) and mediate anti-viral and anti-bacterial activity by
activating inflammatory pathways (1, 8–10). An understanding of
the way in which these compounds affect acquisition of adaptive
immunity and immunological memory is important because they
could be employed for use during influenza pandemics where
there is a high risk of re-exposure to pathogen. In the case of
respiratory diseases, delivery of TLR agonists to the pulmonary
tract can alter the immune environment, which could influence
subsequent induction of adaptive immunity. An understanding
of the way in which immunostimulatory agents, including TLR
agonists, affect development of pathogen-specific immunity is
therefore important.
We have developed a soluble form of the synthetic analog, S-
[2,3-bis(palmitoyloxy)propyl] cysteine (Pam2Cys), which acts as
an agonist of toll-like receptor-2 (TLR-2) and provides immediate
protection against challenge with a lethal dose of influenza virus
A/PR/8/34 (PR8, H1N1) (1). We have also shown that although
Pam2Cys treatment significantly reduces viral burden, reduces
disease symptoms, and prevents death, it does not totally abrogate
infection. This property provides the potential to develop immu-
nity to influenza virus through asymptomatic natural infection.
In this study, we show that Pam2Cys prophylaxis permits devel-
opment of a robust influenza virus-specific adaptive immune
responses comprised CD8+ T-cells, CD4+ T-cells, and antibod-
ies. We also show that this virus-independent stimulation of the
innate immune system does not compromise the development of
heterologous immunity. The development of an agent that can
provide the host with immediate protection and does not hinder
the development of pathogen-specific immunity following expo-
sure to infectious virus provides an opportunity for population
immunity to be achieved through natural exposure to the virus.
Materials and Methods
Synthesis of PEG-Pam2Cys
Pam2Cys is hydrophobic and insoluble in physiological media;
therefore, we synthesized the agonist with a polyethylene glycol
molecule attached to confer solubility and allow administration
by the intranasal (i.n.) route. PEG-Pam2Cys was synthesized in
house using Fmoc-based chemistry as described previously (1).
The product was purified by reversed-phase high-performance
liquid chromatography (HPLC) using a C4 VYDAC column
(10mm 250mm; Alltech, NSW, Australia) installed in a Waters
HPLC system (Waters Millipore, Milford, MA, USA). The purity
of PEG-Pam2Cys was determined by HPLC using a VYDAC C8
column (4.6mm 250mm) installed in a Waters system and was
found to be >95%. The authenticity of the product was determined
by mass analysis (mass value found 1,502.2Da; expected mass
1,502.1Da) using an Agilent 1100 Series LC/MSD ion-trap mass
spectrometer (Agilent, Palo Alto, CA, USA).
Animals
Female C57BL/6 mice (6–12weeks old) were bred and housed
in the Animal house facility at the Department of Microbiol-
ogy and Immunology, The University of Melbourne. All animal
experiments were conducted with approval from the University
of Melbourne Animal Ethics Committee.
Inoculations and Viral Challenge
Mice were anesthetized using isoflurane inhalation and received
either 20 nmol of PEG-Pam2Cys dissolved in saline or saline alone
by the i.n. route.
Mice were challenged with a virulent strain of influenza virus
3 days after treatment with PEG-Pam2Cys. 200 plaque forming
units (PFU) of the H1N1 influenza virus A/Puerto Rico/8/34
(PR8, Mount Sinai) were administered by the i.n. route during
isoflurane anesthesia. Infection following challenge with PR8 in
this way results in weight loss, labored breathing, and a hunched
posture; animals were monitored daily for any signs of illness and
euthanized at a pre-determined humane endpoint.
Challenge with less virulent strains of influenza virus were
also carried out during isoflurane anesthesia with either (i)
104.5 PFU of the H3N1 virus Mem/Bel (a genetic reassortant of
A/Memphis/1/71 [H3N2]A/Bellamy/42 [H1N1]) (ii) 104.5 PFU
of Mem71 A/Memphis/1/71, an H3N2 strain or (iii) 104.5 PFU of
the H3N2 virus, 31. Each virus preparation was diluted in PBS
and administered i.n. 3 days after receiving PEG-Pam2Cys.
Preparation of Lung Cells
Following CO2 asphyxiation, lungs were removed and subjected
to enzymatic digestion with collagenase A (2mg/ml; Roche,
Mannheim, Germany) in RPMI 1640 medium for 30minutes
37°C. Cells were strained through a metal sieve and treated with
ammonium-Tris hydrochloride (7.4% w/v ammonium chloride,
2.06% w/v Tris hydrochloride [ATC]) for 5min at 37°C and
were then washed twice with RP-10 (RPMI 1640 containing 10%
fetal calf serum, 2mM -glutamine, 76mM 2-meceptoethanol,
150U/ml penicillin, 150mg/ml streptomycin, 150mM non-
essential amino acids [all supplements were obtained from Life
Technologies]) in 7.5mMHEPES. The number of viable cells was
determined using trypan blue exclusion.
Intracellular Cytokine Staining
Lung and spleen cells (2–3 106/200µl) were stimulated in the
presence or absence of peptide PA 224–236 or NP366–374 (1µg/ml)
with 5µg/ml of GolgiPlug (BD Biosciences Pharmingen) 25U/ml
recombinant human IL-2 (Roche, Indianapolis, IN,USA) for 6 h at
37°C. Following stimulation, cells were stainedwith PercP5.5 anti-
mouse CD8α (BD Biosciences Pharmingen) then fixed and per-
meabilized using the BD Cytofix/Cytoperm kit (BD Biosciences
Pharmingen) according to the manufacturer’s instructions. Cells
were finally stained with FITC-labeled antibody directed against
interferon-γ (IFN-γ), Pe-Cy7-labeled antibodies directed against
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tumor necrosis factor-α (TNF-α) and APC-labeled antibodies
directed against IL-2. Samples were analyzed using a FACSCanto
II and analyzed using FlowJo Software.
Hemagglutination Inhibition Assay
Sera were prepared from blood and stored at  20°C until use.
To remove any non-specific inhibitors of hemagglutination, sera
were diluted 1/5 with receptor destroying enzyme (RDE II, Denka
Seiken Co., Ltd.) and incubated at 37°C overnight. Sodium cit-
rate (1.6% w/v from Merck; Kilsyth, Victoria) diluted in PBS
(Media Preparation Facility, Department of Microbiology and
Immunology). 0.1% sodium citrate (Chem Supply) was added and
samples were incubated for a further 2 h at 56°C prior to use.
The hemagglutination inhibition (HI) assay was performed using
either Mem/Bel or PR8 according to the method described in Ref.
(11) and modified to a micro-titer format.
In vivo Cytotoxic T-Cell Assay
An in vivo cytotoxic T-cell (CTL) assaywas performed inmice that
had been primed with Mem71 virus and challenged 1month later
with PR8 virus using a previously describedmethod (12). The data
generatedwere analyzed using FlowJo software and the percentage
specific lysis of CFSE-labeled target cells in eachmouse calculated
using the following equation:
% specific lysis = 1  r (non-infected)r (infected)  100
where r = % CFSE lowCFSE high
CD4+ T-Cell IFN-γ Detecting ELISPOT
Membrane-based 96-well plates (MAIPS4510; Millipore, North
Ryde, NSW, Australia) were coated with anti-mouse IFN-γ cap-
ture antibody (clone R4-6A2; Pharmingen) prior to addition of
5 105 cells to each well followed by 50µl NP311–325 peptide
(5µg/well). Four wells lacking peptide were included as nega-
tive controls. Cells were cultured for 18 h at 37°C 5% CO2 and
IFN-γ detected using biotinylated mouse anti-IFN-γ detection
Ab (clone XMG1.2; Pharmingen) and streptavidin–alkaline phos-
phatase (Pharmingen) as described elsewhere (13). Spots formed
by the deposition of enzyme substrate were counted using an
ELISPOT plate reader (AID Autoimmun Diagnotika, Strassberg,
Germany) and analyzed using AID software. The number of spot-
forming units (SFU) was calculated by subtracting the sum of the
background value plus two SD and responses considered positive
when the net SFU value was>20 SFU/106 cells.
Determination of Influenza Virus Titers
Lung viral titers were determined using an MDCK cell-based
plaque assay as previously described (14).
Characterization of the Pulmonary Cytokine
Environment
The levels of IFN-γ, TNF-α, interlukin-6 (IL-6), IL-10, IL-
12p70, and monocyte chemoattractant protein-1 (MCP-1) in
bronchoalveolar lavage (BAL) fluid or lung tissue were analyzed
using a BD Cytometric Bead Array (CBA) Mouse Inflammation
Kit (BD Biosciences, San Diego, CA, USA) according to the man-
ufacturer’s instructions with the exception that a total of 2µl of
each capture bead was used in 50µl of BAL sample and the PE-
detection reagentwas diluted 1 in 5. Sampleswere analyzed using a
BectonDickinson FACSCalibur flow cytometer and data analyzed
using the FlowJo software package (Tree Star, Inc., Ashland, OR,
USA).
Statistical Analyses
For comparison of two data sets, a two-tailed Student’s t-test was
used. For comparison of data sets with a non-Gaussian distribu-
tion, a Mann–Whitney t-test was used. A P-value 0.05 was con-
sidered statistically significant. Statistical analyses were carried
out using the GraphPad Prism 6 software package.
Results
Adaptive Immune Responses Generated
Following Challenge with Virulent and
Non-Virulent Influenza Virus Strains
In the C57BL/6 mouse model of influenza infection, the neutral-
izing Ab response is directed predominantly to the viral hemag-
glutinin and the CD8+ T-cell response is directed to the two
immunodominant epitopes PA224–236 and NP366–374, present on
the internal proteins, acid polymerase and nucleoprotein, respec-
tively (15).
Use of non-virulent Mem–Bel (H3N1) influenza virus allowed
us to follow the adaptive immune response beyond 7 days, the
time point at which mice infected with virulent PR8 (H1N1)
influenza virus succumb to infection. Saline or PEG-Pam2Cys was
administered to mice 3 days prior to challenge with 104.5 PFU of
Mem–Bel virus (Figure 1A), mice were monitored daily follow-
ing influenza challenge and weight loss is shown in Figure 1B.
Animals that received PEG-Pam2Cys maintained their overall
bodyweight throughout the duration of infection, whereas ani-
mals treated with saline lost a small amount of weight during
influenza challenge but regained weight 10 days after influenza
challenge. The viral load in mice treated with PEG-Pam2Cys was
significantly reduced (>1 log) during the early stages of infection
and by day 7, virus was cleared from the lungs of both treatment
groups (Figure 1C).
No significant differences in titers ofHI antibodies (P= 0.4977)
were detected in the sera of saline and PEG-Pam2Cys-treated ani-
mals 10 days after challenge (Figure 1D). Epitope-specific CD8+
T-cell responses were examined 10 days postinfection, and no
significant differences were detected in cytokine secreting CD8+
T-cells present in the lungs or spleens regardless of the treat-
ment received (Figures 1E–G). Gating strategy used to identify
cytokine secreting cells is shown in Figure S1 in Supplementary
Material. We also detected no significant (P= 0.7381) numbers of
CD4+ T-cells in the spleens of each treatment group (Figure 1H).
Taken together, the results suggest that neither cell-mediated nor
humoral immune responses were compromised by pre-treatment
with PEG-Pam2Cys.
To determine the effects of PEG-Pam2Cys on infection with a
more virulent influenza virus, mice were treated with saline or the
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FIGURE 1 | Antibody and cell mediated immune responses generated
in PEG-Pam2Cys-treated mice following infection with Mem/Bel.
(A) Timeline of protocols used; C57BL/6 (n= 5–15) mice were inoculated via
the i.n. route with saline or 20 nmol of PEG-Pam2Cys 3days prior to
challenge with 104.5 PFU of Mem/Bel. At various times following challenge,
mice were culled and various virological and immunological parameters
measured. (B) Percentage weight change following influenza challenge.
(C) Mean viral loads present in the lung throughout the course of infection.
(D) Influenza-specific Ab levels in sera were determined using HI assays.
(E) Representative FACS plots of the NP366–374-specific response in the
lungs of PEG-Pam2Cys and saline-treated mice. Numbers of NP366–374 and
PA224–236 specific cytokine secreting CD8+ T-cells in (F) lungs and
(G) spleen. (H) Number of IFN-γ secreting CD4+ T-cells [spot-forming units
(SFU) per 106 cells] in spleen cells following stimulation with peptide epitope
NP311–325. Statistical significance for (B) was determined using an unpaired
Mann–Whitney t-test (*P<0.05).
immunostimulant and subsequently challenged with a lethal dose
of PR8 virus (Figure 2A). Saline control mice suffered substantial
weight loss and reached the previously determined humane end
point 8 days after challenge (Figure 2B). In contrast, mice pre-
treated with PEG-Pam2Cys all survived viral challenge, a result
which is consistent with our previous findings (1).
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FIGURE 2 | Antibody and cell mediated immune responses
generated in PEG-Pam2Cys-treated mice following challenge with
200 PFU of PR8 influenza virus. (A) Timeline of protocols used;
C57BL/6 (n= 5–10) mice were inoculated via the i.n. route with saline or
20 nmol of PEG-Pam2Cys 3days prior to challenge with 200PFU of PR8.
(B) Mice were monitored daily following viral challenge and the
percentage change in body weight recorded. (C) Hemagglutination
inhibiting Ab levels in sera. (D) Representative FACS plots of the
NP366-374-specific CD8+ T-cell response in lungs. Numbers of NP366–374
or PA224–236 specific cytokine secreting CD8+ T-cells in (E) lungs and (F)
spleen. Statistical significance was determined using an unpaired
Student’s t-test (*P<0.05).
Another group of C57BL/6 mice treated with either saline or
PEG-Pam2Cys and subsequently challenged with PR8 were euth-
anized 7 days after viral challenge to asses the adaptive immune
responses. Non-significant titers of HI antibodies (P= 0.2607)
were detected in sera of animals 7 days after challenge with PR8
virus (Figure 2C) whether they had been pre-treated with saline.
When the fine specificity of the CD8+ T-cell response was exam-
ined, very few differences were detected in the cytokine profiles
of PA224–236 and NP366–374-specific CD8+ T-cells obtained from
lungs and spleen of mice whether treated with saline or PEG-
Pam2Cys (Figures 2D–F). The results again indicate that treat-
ment with PEG-Pam2Cys has little or no deleterious effect on the
development of adaptive immune responses.
PEG-Pam2Cys Treatment does not Affect the
Development of Recall CD8 T-Cell Responses or
the Development of Heterologous Immunity
Because CD8+ T-cells target the internal, conserved epitopes of
the influenza virus proteins, they are able to recognize a broad
range of influenza strains (16). These cells are, however, short
lived and require constant stimulation for persistence. The use of
Mem’71 (H3N2) results in a resolving infection, which allowed us
to track the maintenance of influenza-specific immune responses
and also to determine the ability to provide protection against a
second challenge with a heterologous strain of virus.
To examine the long-term functional and cross-protective capa-
bilities of the CD8+ T-cell response generated, we assessed CD8+
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FIGURE 3 | Influenza-specific cytotoxic CD8+ T-cells persist in the lung
and the spleen of PEG-Pam2Cys-treated mice. (A) Time line of protocol
used; C57BL/6 mice (n= 5) received saline or PEG-Pam2Cys 3days prior to
challenge with 104.5 PFU of Mem71 influenza virus. One month later, mice were
challenged with a lethal dose of PR8. (B) Percentage weight change after
secondary influenza challenge. Seven days after challenge with PR8 naïve
“donor” splenic cells were differentially labeled with CFSE and pulsed with no
peptide, peptide NP366–374, or peptide PA224–236 before intravenous transfer via
the base of tail into recipient mice. Recipient mice were killed and remaining
labeled donor cells in the lungs and spleens enumerated using flow cytometry.
The percentage of specific lysis observed in the lung (C) and spleen (D) are
shown. Each symbol in (C,D) represents the percentage of specific lysis
obtained by individuals and the vertical line indicates the mean of each group.
Numbers above each group indicate the mean amount of specific lysis of each
groups with the SD. Data are from one of the two independent experiments,
which yielded similar results.
T-cell responses using an in vivo CTL assay. Following treat-
ment with PEG-Pam2Cys or saline and subsequent challenge
with Mem’71 (H3N2) virus, mice were then challenged 4weeks
later with a lethal dose of the heterologous PR8 (H1N1) virus
(Figure 3A). The results (Figure 3B) demonstrate that both
groups were protected from lethal PR8 challenge, which typi-
cally causes 20% weight loss by day 7 (Figure 2B), indicating
that treatment with Pam2Cys does not compromise the abil-
ity to elicit and maintain immunity against heterologous virus
challenge.
Seven days after secondary infection splenocytes from naïve,
“donor” mice were pulsed with either PA224–236 peptide, NP366–374
peptide or received no treatment. The cells were then differen-
tially labeled with different concentrations of CFSE and injected
intravenously via the base of tail into recipient mice. After 14 h,
labeled cells present in lungs and spleen were enumerated by
flow cytometry and the gating strategy is shown in Figure S2
in Supplementary Material. The difference in the number of
CFSE-labeled cells in infected mice compared to uninfected mice
revealed that the CD8+ T-cell response generated in mice pre-
treated with PEG-Pam2Cys or saline were equally effective at
killing donor cells (Figures 3C,D). The results clearly demon-
strate that prophylaxis with PEG-Pam2Cys did not compromise
the function or quality of the CD8+ T-cell response generated.
The results of the experiments further demonstrate that the
immunostimulatory effects of PEG-Pam2Cys do not affect the
cytotoxic capabilities of T-cells responsible for influenza-specific
immunity.
To further characterize the CD8+ T-cell response, the cel-
lular cytokine profiles were examined by ICS (Figure 4A) and
the gating strategy is shown in Figure S3 in Supplementary
Material. There were no significant differences in the num-
bers of PA224–236 or NP366–374-specific T-cells capable of secret-
ing a combination of cytokines in the lungs and spleens of
saline and PEG-Pam2Cys treatment groups (Figures 4B–D).
These results confirm our earlier findings (1) that Pam2Cys
does not hinder development of influenza-specific immune
responses. We now show that the influenza-specific immune
response can be recalled by secondary infection with a differ-
ent influenza virus and that these cells possess cytolytic func-
tion and secrete a combination of cytokines associated with
protection.
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FIGURE 4 | Influenza-specific CD8+ T-cell responses persist in the
spleen and lung following stimulation with PEG-Pam2Cys. (A) Timeline of
protocol used; C57BL/6 mice (n= 5) received 20 nmol of PEG-Pam2Cys or
saline 3 days prior to challenge with 104.5 PFU of Mem71. One month after
primary challenge, mice were challenged with PR8 influenza virus, and 7days
later, an ICS assay was performed to examine the cytokine profile of
influenza-specific CD8+ T-cells that were generated. (B) Representative FACS
plots show the percentage of CD8+ T-cells from the spleen secreting either
IFN-γ and/or TNF-α. Numbers of NP366–374 or PA224–236 specific CD8+ T-cells
secreting cytokines in lung (C) and spleen (D). Results are expressed as the
mean (1 SD). Data are from one of the two independent experiments that
yielded similar results.
Pam2Cys Treatment does not Alter Adaptive
Immune Responses Generated in
Immunologically Experienced Mice
Following vaccination or natural infection, human beings are no
longer immunologically naïve. If immunostimulatory agents are
to be used in human beings, we need to determine whether or
not they affect existing antigen specific T-cells. Others (17, 18)
have shown that subsequent and heterologous influenza virus
infections cause an influx of CD8+ T-cells into lungs. These
infections, ormore specifically the inflammation that they induce,
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FIGURE 5 | PEG-Pam2Cys treatment alone does not activate
memory CD8+T-cells. (A) Timeline of protocol used; C57BL/6 mice
were challenged with 104.5 PFU of X31 virus, and 2months later, mice
received either saline or 20 nmol of PEG-Pam2Cys. After 3 days, mice
were euthanized and the CD8+ T-cell responses assessed. (B) Total
number of CD8+ T-cells in the lung. (C) Numbers of PA224–236 specific
CD8+ T-cells secreting IFN-γ, IFN-γ, and TNF-α or IFN-γ, TNF-α, and
IL-2 in the lung. Results are expressed as the mean (1 SD). Statistical
significance is denoted * on the graph and was determined using an
unpaired Student’s t-test (P<0.05).
can lead to the recruitment of cells into the lung (19). What we
have previously observed following treatment of immunologically
naïve animals with PEG-Pam2Cys (1) is an increase in the num-
bers of CD8+ T-cells. We therefore determined whether or not
PEG-Pam2Cys delivered intanasally affected resident CD8+ T-
cells elicited by previous infection. Immunologically experienced
mice were generated by challenge with a non-lethal dose of X31
influenza virus and 2months later, mice were treated with saline
or PEG-Pam2Cys (Figure 5A). We observed an increase in the
number of CD8+ T-cells in lungs of mice treated with PEG-
Pam2Cys (Figure 5B) supporting our earlier observations (1) but
did not observe significant differences in the number and cytokine
profiles of PA224–236 specific CD8+ T-cells (Figure 5C) suggest-
ing that Pam2Cys treatment does not activate memory CD8+
T-cells.
We next determined whether PEG-Pam2Cys altered the ability
of mice to recall a previous immune state. Using the treatment
regime shown in Figure 6A, the PA224–236 specific CD8+ T-cell
response was examined 7 days after challenge with PR8 virus.
Comparable numbers of CD8+ T-cells secreting IFN-γ alone,
IFN-γ plus TNF-α, or IFN-γ plus TNF-α plus IL-2 were detected
in the lungs of mice (Figure 6B). Taken together, the data suggest
that stimulation of the innate immune systemwith PEG-Pam2Cys
does not impact secondary recall responses.
Discussion
In this study, we have shown that PEG-Pam2Cys treatment pro-
vides the host with immediate defense against influenza by reduc-
ing viral burden, eliminating disease symptoms, and also allows
the generation of adaptive immune responses that are quantita-
tively and qualitatively similar to those generated during natural
infection.
The cellular and humoral arms of the adaptive immune system
each combat influenza virus infection and both mitigate disease
severity. It is therefore necessary that immunomodulatory agents
developed to target influenza should not hinder the development
of either armof the adaptive immune response. Even though PEG-
Pam2Cys treatment causes a dramatic reduction (~90%) in anti-
gen load compared with treatment with saline, similar numbers
of CD8+ T-cells were elicited. This is unexpected given previ-
ous findings (20–22) that decreased antigen loads have profound
effects on resulting T-cell responses. Possible explanations for
this are the enhanced proliferation of CD8+ T-cells, due to their
expression of TLR-2, following stimulation with TLR-2 ligands
even in the absence of co-stimulation by APCs (23). Direct acti-
vation of TLR-2 has also been shown to reduce the amount of
antigen required for CD8+ T-cell activation even promoting pro-
liferation of CD8+ T-cells with low TCR and MHC affinity (24).
It seems then that TLR-2-mediated stimulation of CD8+ T-cells
decreases or even obviates the need for co-stimulation by APC
improving the chances for successful CD8+ T-cell responses even
in the presence of reduced antigen and low affinity TCR. Secondly,
inflammation has been shown by many groups to play a crucial
role in the contraction phase and development of memory CD8+
T-cell responses (25–27). The inflammatory milieu induced by
the pathogen has been found to be essential for maximal CD8+
T-cell expansion and is also crucial for the development of effec-
tor functions such as cytolysis (28). Furthermore, Richer and
colleagues (29) have shown that inflammatory cytokines reduce
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FIGURE 6 | Pre-existing adaptive immune responses are not
compromised by stimulation with Pam2Cys. (A) Timeline of infection
protocol used; C57BL/6 mice (n=5) were challenged with 104.5 PFU of 31
virus, and 2months later, mice received either saline or 20 nmol of PEG-Pam2
Cys 3days prior to challenge with a lethal dose of PR8 virus. Mice were
monitored daily following challenge and the PA224–236 specific CD8+ T-cells
secreting cytokine in the lung are shown in (B). Results are expressed as the
mean (1 SD).
antigen sensitivity in both effector and memory CD8+ T-cell
responses.
The development of prophylactic agents that augment the host’s
innate immune system could considerably decrease the morbidity
and mortality rates that are associated with influenza pandemics
for which no vaccines are available or in those cases where
available vaccines are ineffective, e.g., during the 2009 H1N1
influenza pandemic where the only seasonal influenza vaccine
that was available failed to induce immune responses capable of
protecting individuals against the emergent strain (30). Intranasal
administration of PEG-Pam2Cys at such times could provide the
population with immediate protection and reduce transmission
of virus (1). As we show in this study, individuals treated with
Pam2Cys and subsequently challenged with virus would develop
influenza-specific adaptive immune responses providing long-
term protection and removing the need for rapid vaccine produc-
tion. Another feature of PEG-Pam2Cys as an immunostimulatory
agent is that it has the potential to be self-administered reducing
the impact placed on medical staff during pandemics.
We have shown that the TLR-2 agonist PEG-Pam2Cys provides
mice with immediate protection against influenza virus and does
not impact the induction of influenza-specific immunity follow-
ing subsequent exposure to virus, which provides both homotypic
and heterosubtypic protection. The data generated in this study
encourages the development of immunostimulatory agents and
could also alter our perception of the role that these anti-microbial
agents play in long-term immunity to respiratory infections. In the
absence of an effective vaccine, the use of Pam2Cys can imme-
diately reduce the impact of infectious agents and provide an
individual with long-lasting immunity through natural infection.
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